Jonathan Webster, MD, and Nikesh Shah, MD, explore the current role of blinatumomab in acute lymphoblastic leukemia management.
Back
Navigating the Evolving Acute Lymphoblastic Leukemia Treatment Paradigm
Jonathan Webster, MD, and Nikesh Shah, MD, provide a comprehensive overview of the evolving treatment landscape for acute lymphoblastic leukemia (ALL), with a focus on how frontline strategies and immunotherapy integration are reshaping patient outcomes. Across the program, they examine the role of blinatumomab in various clinical contexts, unpack how age and Philadelphia chromosome status influence therapeutic decision-making, and review emerging data for younger adults with BCR::ABL1–negative disease. Webster and Shah also highlight promising research directions and key studies to watch ahead of the 2025 ASH Annual Meeting, underscoring the rapidly advancing science driving future improvements in ALL care.
Navigating the Evolving Acute Lymphoblastic Leukemia Treatment Paradigm
Episodes
All
All
Jonathan Webster, MD, and Nikesh Shah, MD, detail current treatment approaches in frontline acute lymphoblastic leukemia.
Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL.
Jonathan Webster, MD, and Nikesh Shah, MD, discuss data for blinatumomab in younger adult patients with BCR:ABL1–negative B-ALL.
Ongoing research explores the logistics and efficacy of blinatumomab, aiming to enhance patient access and treatment outcomes in leukemia therapy.
Jonathan Webster, MD, and Nikesh Shah, MD, discuss ALL data and research to look out for at ASH 2025.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5